Immupharma Share News (IMM)

UK MIDDAY BRIEFING: GKN A Winner As Earnings Season Hits Full Swing

Immupharma raises £3.4m as it gears up for Lupuzor Phase III trial

Shares in drug developer Immupharma were higher after confirmation it had raised £3.4m at a premium price to help fund Phase III trials of its lead product candidate Lupuzor, a potential treatment for lupus. The new shares were issued, principally from long-time investor Aviva, at a price of 53p per

UK WINNERS & LOSERS: ASOS Back In Style Despite Profit Fall

ImmuPharma Gets EUR400,000 Grant In France For Urelix Technology

Sunday share tips: BG Group, Genel Energy, Palace Capital

Sell shares of BG Group, Danny Fortson advised in the Sunday Times. Credit Suisse analysts have questioned whether the gas producer's big Australian operation will open on time and have said BG's estimates for its Brazilian oil fields are bigger than those of Petrobas, which leads the development. I

ImmuPharma Poised For Phase III Trials Of Lupuzor As Loss As Expected

ImmuPharma Forms European Research Team As Part Of Peptides Drive

ImmuPharma Granted New US Patent For Nucant Cancer Treatments

LONDON (Alliance News) - ImmuPharma PLC said Monday that it had been granted a US patent for a new "optically pure" version of its Nucant family of cancer treatments, providing it with longer exclusivity over the product, and expanding their potential uses to related conditions such as age-relate

Immupharma gains new patents for Nucant treatments

Drug developer Immupharma has improved the patent protection of its Nucant cancer treatments. Immupharma said the US Patent and Trademark Office has granted a notice of allowance for an "optically pure" version of its Nucant family. A similar grant has been obtained from the European Union, Japane

ImmuPharma's patient approach disappoints

Losses from AIM-listed biotech ImmuPharma were less than expected, with the company working hard to commercialise its Lupuzor lupus treatment via phase III clinical trials and new potential partners. Lupuzor has received approval from the US Food and Drug Administration (FDA) to start late-stage t

ImmuPharma Losses Widen As It Accelerates Research And Development

LONDON (Alliance News) - Specialist drug discovery and development company ImmuPharma PLC Wednesday said it losses widened in 2013, as its invests in developing its lupus and cancer treatments. The company posted pretax profit loss of GBP4.4 million for 2013, compared with a GBP4.2 million

ImmuPharma Narrows Losses, Developing Lupus Treatment

ImmuPharma reports half-year loss

ImmuPharma's shares fell in Friday morning trading as the company reported a half-year loss in line with last year. Losses for the first six months of the year remained unchanged at £1.8m and loss per share held steady at 2.17p. The drug discovery and development company said during the period it

Immupharma progresses with cancer treatment trials

ImmuPharma, a drug developer, has reported that its lead cancer programme, IPP-204106, is progressing, and that trials are being conducted at three hospitals across Europe to identify the optimal dose for treating patients. IPP-204106 is 10 times more efficient that the previous Nucant version in p

ImmuPharma non-exec reduces stake

Dr Ajay Agrawal, Non-Executive Director of ImmuPharma, sold a stack of shares in the AIM-listed drug company, it was announced Monday. Agrawal traded in 62,169 shares at 57p a time on January 24th, pocketing £35,436 before tax. The deal was announced the same day the group said its key scientific